Kimia Biosciences Limited has strengthened its board with the appointment of a seasoned pharmaceutical industry veteran. The company announced the appointment of Mr. Kaku Vijaya Shekhar Reddy as Additional Executive Director, bringing over 40 years of pharmaceutical industry experience to the board.

Board Meeting Details

The board meeting was conducted on December 29, 2025, commencing at 7:00 PM and concluding at 8:00 PM. The primary agenda item was the consideration and approval of the directorial appointment under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

New Director Profile and Experience

Mr. Kaku Vijaya Shekhar Reddy (DIN: 00800172) brings substantial industry expertise to the company's leadership team. His appointment details and qualifications are outlined below:

Mr. Reddy is a seasoned pharmaceutical professional with over 40 years of experience in the Active Pharmaceutical Ingredients (API) manufacturing sector. His extensive expertise spans multiple critical areas including operations management, greenfield and brownfield project execution, regulatory compliance, process development, and business strategy.

Leadership Experience and Achievements

Throughout his distinguished career, Mr. Reddy has held several senior leadership positions in reputed pharmaceutical organizations. His previous roles include:

• Managing Director
• Director (Technical)
• Chief Operating Officer
• Vice President – Operations
• General Manager – Operations

He has successfully led multiple large-scale manufacturing projects and has been instrumental in commercializing several API molecules, demonstrating his operational excellence and strategic capabilities in the pharmaceutical sector.

Regulatory Compliance and Independence

The appointment adheres to all regulatory requirements and disclosure norms. Key compliance aspects include:

Shareholder Approval Process

While the board has approved Mr. Reddy's appointment as Additional Executive Director, the appointment remains subject to approval by the company's shareholders. This procedural requirement ensures proper governance and stakeholder participation in key leadership decisions.

The appointment reflects Kimia Biosciences' commitment to strengthening its leadership team with experienced professionals who can contribute to the company's growth and operational excellence in the competitive pharmaceutical industry.

Kimia Biosciences , a prominent player in the Indian pharmaceutical sector, has released its unaudited financial results for the quarter and half-year ended September 30, 2025. The company's Board of Directors approved these results during a meeting held on November 14, 2025, as per the regulatory filing with the BSE.

Financial Highlights

The company's performance for the second quarter shows resilience in a challenging economic environment. Here's a breakdown of the key financial metrics:

Cash Flow and Financial Position

For the half-year period, Kimia Biosciences reported:

While the company has shown positive cash flow from operations, it's worth noting that Kimia Biosciences faced some financial challenges, including:

• Increased borrowings
• Higher finance costs

These factors suggest that the company may be navigating through a period of financial adjustments or expansion that requires additional capital.

Corporate Governance and Compliance

The financial results were approved in a Board meeting that commenced at 7:00 PM and concluded at 8:00 PM on November 14, 2025. This meeting was held at the company's corporate office located at 974, 9th floor, Aggarwal Millennium Tower-II, Netaji Subhash Place, New Delhi-110034.

In compliance with SEBI regulations, the company has:

1. Approved the unaudited financial results on a standalone basis for Q2 and H1.
2. Taken on record the limited review report issued by the statutory auditors.

Market Implications

The reported net profit of Rs 101.40 lakhs indicates that Kimia Biosciences has maintained profitability despite the increased financial costs. This could be viewed positively by investors, especially considering the challenging economic conditions many businesses are facing.

However, the increase in borrowings and finance costs warrants attention. Investors and analysts may want to keep an eye on how the company manages its debt and uses the borrowed funds to drive growth or operational improvements in the coming quarters.

The pharmaceutical sector, being essential and relatively resilient, often attracts investor interest. Kimia Biosciences' performance in this context may be of particular interest to those tracking the Indian pharma industry's growth and challenges.